Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
Xinxin Wang, Xi Zhang(Army Medical University), Dingsong Zhang, Le Luo(Xinjiang Technical Institute of Physics & Chemistry), Jianning Ge, Chunhui Yang, Xun Ye(Capital Medical University), Yingnian Chen, Zhongtao Yuan, Yu Han, Ruihao Huang(Army Medical University), Lihua Fang(Fujian Medical University), Sanbin Wang(117th Hospital of People's Liberation Army), Yu Li(Zhejiang Chinese Medical University), Lin Liu(Wuxi People's Hospital), Jia Liu(Frederick National Laboratory for Cancer Research), Zhimin Li, Yao Liu(Chongqing University), Shiqi Li(University of Science and Technology of China), Cheng Zhang(Army Medical University), Kun Wu(Kunming Medical University), Lei Gao(Zhejiang Chinese Medical University), Jiaping He, Youcheng Wang, Xu Tan(Army Medical University), Duanpeng Wang, Wei Cao(Academy of Military Medical Sciences)
Cited by 30
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234
HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
|Journal of Biological Chemistry|2008|174
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
|Frontiers in Oncology|2019|115
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
|Nature Chemical Biology|2020|114